Company intelligence / Profile preview

Acuvax

Perth, Western Australia, Australia

Ownership: Private
Development stage: Other

Overview

Acuvax was an Australian biotechnology company focused on the development and commercialization of vaccine technologies for infectious diseases. The company's portfolio was centered on recombinant protein vaccines, most notably a candidate for West Nile Virus which reached Phase 1 clinical trials. Acuvax held a significant stake in Hawaii Biotech and possessed rights to the ISCOMATRIX adjuvant technology through a partnership with CSL Limited. The company also explored vaccine candidates for Dengue Fever, Malaria, and Influenza (SoluVax). Due to financial constraints, Acuvax eventually ceased its biotechnology operations and the corporate entity was repurposed for a reverse takeover in 2017.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Partnerships

CSL Limited

Beyond the preview

Go deeper on Acuvax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acuvax.

Explore the full profile